A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
31actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-15 | actual | When the study began enrolling |
| Primary completion | 2025-03-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-06 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: AZD5004 — also filed as ECC5004
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
measured From screening (Day -28) to last follow up visit (Day 120)
Part B: Maximum observed plasma (peak) drug concentration (Cmax) of AZD5004
measured From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)
Part B: Area under the concentration-curve from time zero to the last quantifiable concentration (AUClast)
measured From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)
Part B: Area under concentration-time curve from time 0 to infinity (AUCinf)
measured From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)
Part B: Time to reach maximum observed concentration (tmax)
measured From Day 1 (Treatment Period 1) to Day 13 (end of Treatment Period 2)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed